ARVO 2026 Milestone: Next-Generation D.I.M.S. Spectacle Lenses Halt Myopia Progression in 9 Out of 10 Children

For the past decade, the clinical consensus in pediatric myopia management held that optical interventions could significantly slow—but rarely completely arrest—refractive progression and axial elongation during peak childhood growth years. That ceiling was shattered at the 2026 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Denver, where HOYA Vision Care and researchers from The Hong Kong Polytechnic University presented randomized controlled trial (RCT) results showing that the new MiYOSMART iQ spectacle lens halted clinically relevant myopia progression in 9 out of 10 children over their first year of wear.

Inside the 196-Child Randomized Controlled Trial and Axial Length Data

Building on the foundational Defocus Incorporated Multiple Segments (D.I.M.S.) architecture that revolutionized myopia control spectacle prescribing worldwide, the MiYOSMART iQ design introduces an advanced next-generation optical profile engineered to intensify simultaneous myopic defocus across the mid-peripheral retina while preserving crisp central visual acuity.

Across 196 myopic schoolchildren aged 4 to 12 who completed the rigorous 12-month randomized controlled clinical trial in Hong Kong, participants fitted with MiYOSMART iQ lenses exhibited zero average refractive progression at the one-year mark. Even more remarkably for ocular health specialists, mean axial elongation in the treatment cohort remained at or below the physiological eye growth rates observed in age-matched emmetropic children.

• 90% Progression Halt: Nine out of ten children wearing MiYOSMART iQ spectacle lenses experienced no clinically relevant myopia progression over 12 months.
• Emmetropic Axial Growth Profile: Axial elongation—the primary biomechanical driver of sight-threatening retinal pathology—was suppressed to levels comparable with non-myopic children.
• Validated Down to Age 4: Demonstrated robust efficacy and wearability in preschool children as young as four years old, a global first for D.I.M.S. spectacle technology.
• Highest Reported D.I.M.S. Efficacy: Sets a new clinical benchmark for non-invasive spectacle-based myopia control presented at ARVO 2026.

In a 196-child randomized controlled trial presented at ARVO 2026, next-generation MiYOSMART iQ D.I.M.S. lenses reduced axial elongation to levels comparable with emmetropic peers.

Addressing the Early-Onset Preschool Myopia Challenge (Ages 4–6)

One of the most clinically consequential aspects of the PolyU and HOYA dataset is the inclusion of children as young as age four. Epidemiological studies consistently show that the earlier myopia manifests in childhood, the faster axial length accelerates and the higher the lifetime risk of myopic maculopathy, retinal detachment, and posterior staphyloma.

Historically, clinicians treating four- and five-year-old progressive myopes faced limited evidence-based optical choices, as contact lens modalities can be challenging for very young families to handle and earlier spectacle trials focused primarily on children aged six to eight and above. Validating high-efficacy D.I.M.S. optics across the 4-to-12 age spectrum empowers optometrists to intervene the moment myopic shifts appear.

Reshaping Pediatric Standard of Care Across Canadian Optometry Clinics

For Canadian eye care professionals—where provincial associations have already declared myopia management a standard of care—the ARVO 2026 findings provide compelling chairside evidence when counseling hesitant parents. When families learn that a non-invasive spectacle lens can arrest progression in 90% of wearers during the crucial first year, treatment acceptance rises dramatically.

Combined with optical biometry tracking and outdoor daylight guidance, next-generation D.I.M.S. architectures like MiYOSMART iQ move clinical optometry closer than ever to preventing high myopia before it can take root.